Unlikely partnerships drive drug value in new health economy

10 July 2015

A new report just released from PwC’s Health Research Institute (HRI) explains that the way we discover and measure drug value is drastically changing.

In order to meet changing demands of key health stakeholders, biotech/pharma companies, insurers, technology companies and patients are all collaborating in new ways in the health industry with one common theme: to use newly-available consumer health data to uncover the truth about drug value and its relationship to health outcomes.

Collaborations and companies cited in the report include:

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical